Tuesday April 24, 2018 0 comments
DENVER -- Colorado BioScience Association (CBSA) announced five new members elected to its board of directors during the organization’s annual board retreat on April 19.
Newly appointed board members are:
Jim Cloar, Zimmer Biomet, VP & chief commercial officer, Spine & Robotics
Gino DiSciullo, Prevacept Infection Control, CEO
Charlie Kang, CFO, Ocugen
Ethan Mann, Sharklet, COO
Steve Warnecke, CereScan, board member & CFO; VetDC, chair & CFO; Evolutionary Genomics, chair & CEO
Board members renewing their terms are:
Larry Blankenship, Evergreen Research, director
Gary Connell, Sheridan Ross, co-president, shareholder
Brent Fassett, Cooley partner
Mark Lupa, High Country Venture partner
Fintan Steele, SomaLogic, chief communications and culture officer
Kiki Traylor, M.D., Amgen, director of State Government Affairs
Steve VanNurden, Fitzsimons Innovation Campus, president & CEO
Dan Wittenberg, Snell & Wilmer partner
Shelly Zelin, AlloSource VP of Human Resources
“It’s an honor to welcome Jim, Gino, Charlie, Ethan and Steve to the CBSA board,” said Scott Larson, CBSA board chair. “They represent leading Colorado digital health, biotech and medical device companies working to advance health care and improve lives.
“I look forward to drawing on their expertise as CBSA works to shape the future of our sector.”
“Colorado’s rapid growth brings new opportunities and talent to our state,” said April Giles, CBSA president and CEO.
“CBSA leads policy and advocates for a business environment that supports all stages of innovation. We extend a warm welcome to our new board members and their perspectives.
“We also want to thank our outgoing board members for their commitment to Colorado BioScience Association, with a special thanks to our former board chairman Mark Spiecker for his leadership and dedicated service to CBSA.”
CBSA board members commit to a three-year term and work in partnership with CBSA staff to support the growth of Colorado’s 720 life science companies.